Real‐world clinical experience with serum <scp>MOG</scp> and <scp>AQP4</scp> antibody testing by live versus fixed cell‐based assay
LCBA-FACS for both MOG-IgG and AQP4-IgG had markedly better sensitivity than FCBA-IF, with similar specificity. The use of FCBA-IF may result in underrecognition of both MOG antibody-associated disease (MOGAD) and AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD).
Authors
- Patrizio Caturegli (ORCID: https://orcid.org/0000-0001-6768-6308)
- Eoin P. Flanagan (ORCID: https://orcid.org/0000-0002-6661-2910)
- LuAnn Rezavi
- Matthew D. Smith (ORCID: https://orcid.org/0000-0001-6614-569X)
- Angeliki Filippatou (ORCID: https://orcid.org/0000-0003-0419-233X)
- Elias S. Sotirchos (ORCID: https://orcid.org/0000-0002-8812-1637)
- Peter A. Calabresi (ORCID: https://orcid.org/0000-0002-7776-6472)
- Yasmin Resto
- Yana Said (ORCID: https://orcid.org/0009-0004-4350-1910)
- John Jing-Wei Chen (ORCID: https://orcid.org/0000-0003-3644-7528)
- Conlan Tran (ORCID: https://orcid.org/0000-0001-6015-849X)
- Sean Joseph Pittock (ORCID: https://orcid.org/0000-0002-6140-5584)
- Kai Guo (ORCID: https://orcid.org/0000-0001-8972-2015)
Institutions
- Mayo Clinic (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1002/acn3.52310
- Citations
- 23
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 33.85
Funders
- National Institutes of Health
- NIH Clinical Center